Watch hVIVO’s July 2024 Capital Markets Day here
Yamin 'Mo' Khan
CEO at hVIVO
"The mid- and long-term outlook for the Group is excellent. We have laid foundations for future growth, expanded our service offerings organically and diversified to a wider range of revenue streams through the CRS acquisition. As such, I believe we have significantly strengthened and diversified the business and have enhanced our ability to deliver our target of growing Group revenue to £100 million by 2028."
A rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early clinical development services for our broad and longstanding global client base of biopharma companies.
Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.
CRS is a leading early phase CRO with state-of-the-art research units in Germany, excelling in innovative solutions for early clinical development, from First-in-Human studies to Proof-of-Concept trials in patients.
hLAB is a highly specialised virology and immunology laboratory offering a suite of services to support pre-clinical and clinical respiratory drug and vaccine discovery & development.
FluCamp welcomes participants to take part in our clinical trials under expertly supervised conditions.
